The earnings call highlighted significant advancements in Kymera's clinical programs and strategic collaborations, bolstering its financial position and setting the stage for future growth. Despite some uncertainties in dose selection and program transitions, the positive momentum and strong financial backing indicate a promising outlook.

Company Guidance

During Kymera Therapeutics' second quarter 2025 results call, the company provided guidance on several key metrics and future plans. They reported a cash balance of approximately $1 billion as of the end of July, extending their cash runway into the second half of 2028. This financial position is bolstered by a $288 million follow-on offering and an upfront payment from a collaboration with Gilead. The company achieved $11.5 million in revenue for the quarter, attributed to their collaboration with Sanofi. Research and development expenses were $78.4 million, with $8 million as non-cash stock-based compensation, while general and administrative expenses stood at $17.6 million, including $7.4 million in non-cash stock-based compensation. Kymera announced significant progress in their STAT6 and IRF5 programs, with plans to initiate Phase IIb studies for KT-621 in atopic dermatitis and asthma later this year and early next, respectively. They also highlighted two strategic partnerships: one with Gilead for a molecular glue degrader targeting CDK2 and another with Sanofi focusing on the IRAK4 program, emphasizing the potential to realize significant milestones from these collaborations.

Positive Results from KT-621 Trial

The KT-621 trial in healthy volunteers exceeded expectations, surpassing the target product profile with more than 95% degradation in both skin and blood at low doses.

Strong Financial Position

Kymera raised $288 million in a follow-on offering, extending its cash runway into the second half of 2028, with a current cash position of $1 billion.

Strategic Collaborations

Kymera announced partnerships with Gilead for a CDK2 degrader and Sanofi for the IRAK4 program, potentially unlocking significant milestone payments and expanding the company's reach.

Phase IIb KT-621 Trials on Track

The company has selected doses for the Phase IIb studies in AD and asthma, with the AD trial set to begin in the fourth quarter of 2025.

Advancement of IRF5 Program

The oral IRF5 program is progressing through IND-enabling studies with plans to enter Phase I testing in early 2026.

Kymera Therapeutics (KYMR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KYMR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.74 / -	-0.82	―	―	―
Aug 11, 2025	2025 (Q2)	-0.81 / -0.95	-0.58	-63.79% (-0.37)
May 09, 2025	2025 (Q1)	-0.91 / -0.82	-0.69	-18.84% (-0.13)
Feb 27, 2025	2024 (Q4)	-0.78 / -0.88	-0.25	-252.00% (-0.63)
Oct 31, 2024	2024 (Q3)	-0.83 / -0.82	-0.9	8.89% (+0.08)	―
Aug 07, 2024	2024 (Q2)	-0.68 / -0.58	-0.67	13.43% (+0.09)	―
May 02, 2024	2024 (Q1)	-0.72 / -0.69	-0.7	1.43% (+0.01)	―
Feb 22, 2024	2023 (Q4)	-0.40 / -0.25	-0.6	58.33% (+0.35)	―
Nov 02, 2023	2023 (Q3)	-0.64 / -0.90	-0.79	-13.92% (-0.11)	―
Aug 03, 2023	2023 (Q2)	-0.64 / -0.67	-0.78	14.10% (+0.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KYMR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$40.62	$37.68	-7.24%
May 09, 2025	$30.77	$30.07	-2.27%
Feb 27, 2025	$35.36	$30.25	-14.45%
Oct 31, 2024	$47.67	$46.17	-3.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kymera Therapeutics, Inc. (KYMR) report earnings?

Kymera Therapeutics, Inc. (KYMR) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Kymera Therapeutics, Inc. (KYMR) earnings time?

Kymera Therapeutics, Inc. (KYMR) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KYMR EPS forecast?

KYMR EPS forecast for the fiscal quarter 2025 (Q3) is -0.74.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing